Yes, metformin can make you constipated, though it is far less common than the diarrhea most people associate with the drug. Constipation affects roughly 10 to 17 percent of metformin users in clinical reports, versus 20 to 50 percent who develop loose stools or diarrhea. The mechanism is mostly indirect: metformin changes gut motility, alters bile acid recycling, and shifts the gut microbiome, and any of these can slow transit in susceptible people. It is almost never dangerous on its own, but it can become a real quality-of-life problem, and it occasionally signals something that needs medical attention. Most cases respond to dose timing, hydration, fiber, and formulation changes rather than stopping the drug.
How Metformin Slows the Gut
Metformin's best-known gut effect is speed, not slowness. It accumulates in the small intestine at concentrations 10 to 100 times higher than in blood, and that local load is what drives the nausea, cramping, and diarrhea that define metformin intolerance. Constipation is the less-traveled branch of the same pathway.
The drug does several things at once in the gut. It inhibits complex I of the mitochondrial electron transport chain in enterocytes, which reduces cellular energy availability and changes how the intestinal lining absorbs and secretes fluid. It increases serotonin release from enterochromaffin cells, and serotonin is a motility signal that can push transit either direction depending on receptor and segment. It also raises GLP-1 secretion, which slows gastric emptying and intestinal transit. That last effect is the most plausible constipation driver: slower upper-gut emptying means slower everything downstream.
There is a second, less obvious route. Metformin alters bile acid metabolism by changing the gut bacteria that deconjugate and recycle bile acids. Bile acids are natural laxatives; when the pool shifts, stool can firm up. In plain terms: metformin tinkers with the chemical signals that tell your gut how fast to move, and in some people the net result is slower.
A third factor is often overlooked: metformin does not cause constipation in a vacuum. It is usually prescribed alongside dietary changes, reduced fluid intake from appetite loss, and sometimes other drugs. Those add up.
How Common Is Constipation on Metformin?
The numbers vary by study design, which is why you see a wide range. Pooled trial data put GI side effects of any kind at 20 to 30 percent, with diarrhea dominating. Constipation specifically shows up in roughly 10 to 17 percent of users in labeled and observational data. A reasonable working figure is about 1 in 6, and it is more likely in people who already trend toward slow transit.
| GI side effect | Approximate share of metformin users | Typical timing |
|---|---|---|
| Diarrhea or loose stools | 20–50% | First 1–4 weeks, often dose-related |
| Nausea | 10–25% | First days to weeks |
| Abdominal cramping | 10–20% | Early, dose-related |
| Constipation | 10–17% | Days to months, less dose-tied |
| Metallic taste | 3–10% | Early, usually transient |
The comparison matters clinically. Because diarrhea is so much more common, constipation on metformin is often missed or blamed on something else. If you start metformin and notice harder, less frequent stools within the first month, the drug belongs on your short list of suspects.
The Timeline: When Constipation Shows Up
Constipation from metformin tends to behave differently from diarrhea. Diarrhea usually clusters in the first weeks and eases as the body adapts or the dose is titrated down. Constipation can appear early but often emerges later, especially after dose increases or when extended-release formulations are swapped in.
| Timeframe | What typically happens | What it usually means |
|---|---|---|
| Days 1–7 | Nausea, cramping, possible loose stools | Normal adaptation, not constipation yet |
| Weeks 1–4 | Diarrhea peaks; constipation can begin | Dose is still stabilizing |
| Weeks 4–12 | Most GI effects settle | Persistent constipation is worth addressing |
| Months 2–6 | Constipation may surface after dose increase | Check the dose and formulation |
| Beyond 6 months | New constipation is less likely drug-only | Look for other causes, including B12 |
| Any time | Hard stools with normal fiber intake | Consider extended-release switch |
One pattern stands out: constipation that begins after a dose increase from 500 mg to 1,000 mg twice daily, or after switching from immediate-release to extended-release, is common enough to be predictable. The extended-release form smooths peak drug levels, which helps diarrhea but does not always help constipation.
Why Some People Get Constipated and Others Get Diarrhea
The same drug produces opposite effects in different people, and the reason is partly genetic, partly microbial, partly situational. Gut transit at baseline is the biggest predictor: people who already have slow-transit constipation or irritable bowel syndrome with constipation are far more likely to tip into constipation on metformin.
Gut microbiome composition matters too. Metformin enriches Akkermansia muciniphila and changes short-chain fatty acid production, and the direction of that shift varies with the starting community. Two people with identical doses can end up with different stool consistency because their bacterial starting points differ.
Dose and formulation are the levers you can actually pull. Higher total daily doses and immediate-release tablets produce bigger local gut exposure. Extended-release tablets reduce peak concentrations and are the usual first fix for any GI complaint, though they are more reliably helpful for diarrhea than constipation.
Edge cases deserve mention. People over 65, people with low fluid intake, and people taking calcium channel blockers, opioids, iron supplements, or anticholinergics are already primed for constipation; metformin can be the straw. Pregnancy and significant weight loss on a GLP-1 plus metformin stack also shift the equation, since GLP-1 drugs independently slow transit.
Correcting the Common Misconceptions
The first misconception is that metformin only causes diarrhea. Labeling and patient forums reinforce this, so constipation gets under-recognized. It is real and not rare.
The second is that constipation means you are dehydrated and should just drink more water. Hydration helps, but the mechanism here is motility and bile acid chemistry, not simple water balance. If water alone fixed it, it would not persist for months.
The third is that a bowel habit change on metformin is harmless and ignorable. Usually it is benign, but a new, persistent change in bowel habit in an adult over 45 deserves a clinician's look, independent of the drug, because the timing can mask other causes.
A subtler correction involves vitamin B12. Long-term metformin use is associated with B12 deficiency, and B12 deficiency can cause neuropathy and, less commonly, contribute to constipation through autonomic effects. The American Diabetes Association has recommended periodic B12 measurement in metformin users since its 2017 standards, and that guidance still stands. If constipation appears after years on the drug, B12 is worth checking. This is a hypothesis-level link for constipation specifically, not established causation, but it is a reasonable screening step.
When Constipation Is a Red Flag
Most metformin-related constipation is annoying, not dangerous. Some presentations are not. Seek urgent care for any of the following:
- No bowel movement for more than three days with severe abdominal pain, vomiting, or a rigid, distended abdomen
- Blood in the stool or black, tarry stools
- Unexplained weight loss alongside the bowel change
- New constipation with fever or chills
- Constipation that alternates with pencil-thin stools in someone over 45
- Inability to pass gas at all, which can signal obstruction
These are not typical metformin effects. They point to obstruction, bleeding, or another diagnosis that needs evaluation, and no dose adjustment should be attempted first.
What to Actually Do About Metformin Constipation
Start with the drug itself, because that is the most reversible lever. Ask your prescriber about switching from immediate-release to extended-release metformin; this is the standard first step and helps a meaningful share of people. If the dose was recently increased, ask whether a step back is reasonable. Never stop or change the dose on your own, especially if metformin is controlling blood sugar or part of a combination regimen.
Then address the inputs. Aim for 25 to 30 grams of fiber daily from food first, and increase it gradually over two weeks to avoid bloating. Target roughly 1.5 to 2 liters of fluid daily unless you have a fluid restriction. Add 20 to 30 minutes of walking most days, since physical activity is one of the few things that reliably speeds colonic transit. If these are already in place, an osmotic laxative such as polyethylene glycol is a reasonable short-term bridge and is generally compatible with metformin; stimulant laxatives are better avoided as a habit.
Time the dose with food. Taking metformin with the largest meal reduces peak gut exposure and is standard advice for GI tolerance. If you take it twice daily, splitting doses evenly rather than clustering them helps.
Keep a simple log for two to four weeks: stool frequency, Bristol stool scale score, fluid intake, and dose timing. That record turns a vague complaint into something a clinician can act on, and it distinguishes drug effect from a dietary or other cause.
Finally, set a review point. If constipation has not improved after four weeks of formulation change, fiber, fluid, and activity, ask for a full medication review and, if you have been on metformin for years, a B12 level. Per the American Diabetes Association's longstanding guidance, B12 should be measured periodically in long-term metformin users, and unexplained bowel changes are a fair trigger to check.
What the Evidence Does and Does Not Say
The mechanism story here is partly established and partly inferred. Metformin's effect on gut serotonin, GLP-1, bile acids, and the microbiome is well documented in trials and animal models. That these pathways can slow transit is biologically plausible and supported by the diarrhea-to-constipation spectrum seen in practice. But large, dedicated trials of metformin-induced constipation specifically are scarce; most incidence figures come from side-effect tables in broader diabetes trials and observational cohorts, which undercount mild cases and vary in definition. The 10 to 17 percent range reflects that heterogeneity.
The B12–constipation link is the weakest claim in this article and is presented as a screening consideration, not a proven cause. The red-flag list and the four-week review point are the parts to take most seriously. Constipation on metformin is common enough to expect, usually manageable, and rarely a reason to abandon a drug that is doing its job.